Patents by Inventor William E. Holmes

William E. Holmes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190060213
    Abstract: This invention is a novel method of manufacture for hand-sanitizing lotions that retains the added benefits of prolonged effectiveness while avoiding demulsification as well as the resulting product. The invention presents a novel, more simplified process comprising a lower cooking temperature and an optimized ingredient addition protocol, designed for product stability and ingredient integrity.
    Type: Application
    Filed: August 28, 2018
    Publication date: February 28, 2019
    Inventors: Emmanuel D. Revellame, William E. Holmes
  • Patent number: 7923221
    Abstract: The invention relates to processes for producing an immunoglobulin or an immunologically functional immunoglobulin fragment containing at least the variable domains of the immunoglobulin heavy and light chains. The processes can use one or more vectors which produce both the heavy and light chains or fragments thereof in a single cell. The invention also relates to the vectors used to produce the immunoglobulin or fragment, and to cells transformed with the vectors.
    Type: Grant
    Filed: April 13, 1995
    Date of Patent: April 12, 2011
    Assignees: Genentech, Inc, City of Hope
    Inventors: Shmuel Cabilly, Herbert L. Heyneker, William E. Holmes, Arthur D. Riggs, Ronald B. Wetzel
  • Patent number: 7601827
    Abstract: Novel 2 polypeptides with binding affinity for the p185HER2 receptor, designated heregulin 2-? and heregulin 2-?, have been identified and purified from human tissue. The cDNA encoding the novel heregulin 2-? has been isolated from human tissue and sequenced. Provided herein is nucleic acid sequence of the heregulin 2-? useful in the production of heregulin 2-? by recombinant means. Further provided an amino acid sequence of heregulin 2-? and heregulin 2-?. Heregulins and their antibodies are useful as therapeutic agents and in diagnostic methods.
    Type: Grant
    Filed: September 12, 2005
    Date of Patent: October 13, 2009
    Assignee: Genentech, Inc.
    Inventors: Richard L. Vandlen, William E. Holmes
  • Patent number: 6953842
    Abstract: Novel 2 polypeptides with binding affinity for the p185HER2 receptor, designated heregulin 2-? and heregulin 2-?, have been identified and purified from human tissue. The cDNA encoding the novel heregulin 2-? has been isolated from human tissue and sequenced. Provided herein is nucleic acid sequence of the heregulin 2-? useful in the production of heregulin 2-? by recombinant means. Further provided an amino acid sequence of heregulin 2-? and heregulin 2-?. Heregulins and their antibodies are useful as therapeutic agents and in diagnostic methods.
    Type: Grant
    Filed: December 17, 2001
    Date of Patent: October 11, 2005
    Assignee: Genentech, Inc.
    Inventors: Richard L. Vandlen, William E. Holmes
  • Publication number: 20030023035
    Abstract: Novel 2 polypeptides with binding affinity for the p185HER2 receptor, designated heregulin 2-&agr; and heregulin 2-&bgr;, have been identified and purified from human tissue. The cDNA encoding the novel heregulin 2-&agr; has been isolated from human tissue and sequenced. Provided herein is nucleic acid sequence of the heregulin 2-&agr; useful in the production of heregulin 2-&agr; by recombinant means. Further provided an amino acid sequence of heregulin 2-&agr; and heregulin 2-&bgr;. Heregulins and their antibodies are useful as therapeutic agents and in diagnostic methods.
    Type: Application
    Filed: December 17, 2001
    Publication date: January 30, 2003
    Applicant: Genentech, Inc.
    Inventors: Richard L. Vandlen, William E. Holmes
  • Patent number: 6399746
    Abstract: Novel polypeptides with binding affinity for the p185HER2 receptor, designated heregulin 2-&agr; and heregulin 2-&bgr;, have been identified and purified from human tissue. The cDNA encoding the novel heregulin 2-&agr; has been isolated from human tissue and sequenced. Provided herein is nucleic acid sequence of the heregulin 2-&agr; useful in the production of heregulin 2-&agr; by recombinant means. Further provided an amino acid sequence of heregulin 2-&agr; and heregulin 2-&bgr;. Heregulins and their antibodies are useful as therapeutic agents and in diagnostic methods.
    Type: Grant
    Filed: October 14, 1998
    Date of Patent: June 4, 2002
    Assignee: Genentech, Inc.
    Inventors: Richard L. Vandlen, William E. Holmes
  • Patent number: 6331415
    Abstract: The invention relates to processes for producing an immunoglobulin or an immunologically functional immunoglobulin fragment containing at least the variable domains of the immunoglobulin heavy and light chains. The processes can use one or more vectors which produce both the heavy and light chains or fragments thereof in a single cell. The invention also relates to the vectors used to produce the immunoglobulin or fragment, and to cells transformed with the vectors.
    Type: Grant
    Filed: June 10, 1988
    Date of Patent: December 18, 2001
    Assignee: Genentech, Inc.
    Inventors: Shmuel Cabilly, Herbert L. Heyneker, William E. Holmes, Arthur D. Riggs, Ronald B. Wetzel
  • Patent number: 5859206
    Abstract: Novel polypeptides with binding affinity for the p185.sup.HER2 receptor, designated heregulin 2-.alpha. and heregulin 2-.beta., have been identified and purified from human tissue. The cDNA encoding the novel heregulin 2-.alpha. has been isolated from human tissue and sequenced. Provided herein is nucleic acid sequence of the heregulin 2-.alpha. useful in the production of heregulin 2-.alpha. by recombinant means. Further provided an amino acid sequence of heregulin 2-.alpha. and heregulin 2-.beta.. Heregulins and their antibodies are useful as therapeutic agents and in diagnostic methods.
    Type: Grant
    Filed: April 11, 1995
    Date of Patent: January 12, 1999
    Assignee: Genentech, Inc.
    Inventors: Richard L. Vandlen, William E. Holmes
  • Patent number: 5856110
    Abstract: Novel 2 polypeptides with binding affinity for the p185.sup.HER2 receptor, designated heregulin 2-.alpha. and heregulin 2-.beta., have been identified and purified from human tissue. The cDNA encoding the novel heregulin 2-.alpha. has been isolated from human tissue and sequenced. Provided herein is nucleic acid sequence of the heregulin 2-.alpha. useful in the production of heregulin 2-.alpha. by recombinant means. Further provided an amino acid sequence of heregulin 2-.alpha. and heregulin 2-.beta.. Heregulins and their antibodies are useful as therapeutic agents and in diagnostic methods.
    Type: Grant
    Filed: May 12, 1995
    Date of Patent: January 5, 1999
    Assignee: Genentech, Inc.
    Inventors: Richard L. Vandlen, William E. Holmes
  • Patent number: 5856457
    Abstract: The cDNA encoding a member of or a class of novel PF4A receptors has been identified in human tissue. Provided herein is nucleic acid sequence of a PF4A receptor (the IL-8 receptor) useful as a diagnostic and in the recombinant preparation of PF4A receptors. The PF4A receptor is used in the preparation and purification of antibodies capable of binding to the receptor, and in diagnostic assays.
    Type: Grant
    Filed: March 24, 1995
    Date of Patent: January 5, 1999
    Assignee: Genentech, Inc.
    Inventors: James Lee, William E. Holmes, William I. Wood
  • Patent number: 5840525
    Abstract: A novel polypeptide with binding affinity for the p185.sup.HER2 receptor, designated heregulin-.alpha., has been identified and purified from cultured human cells. DNA sequences encoding additional heregulin polypeptides, designated heregulin-.alpha., heregulin-.beta.1, heregulin-.beta.2, heregulin-.beta.2-like, and heregulin-.beta.3, have been isolated, sequenced and expressed. Provided herein are nucleic acid sequences encoding the amino acid sequences of heregulins useful in the production of heregulins by recombinant means. Further provided are the amino acid sequences of heregulins and purification methods therefor. Heregulins and their antibodies are useful as therapeutic agents and in diagnostic methods.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: November 24, 1998
    Assignee: Genentech, Inc.
    Inventors: Richard L. Vandlen, William E. Holmes
  • Patent number: 5834229
    Abstract: Novel 2 polypeptides with binding affinity for the p185.sup.HER2 receptor, designated heregulin 2-.alpha. and heregulin 2-.beta., have been identified and purified from human tissue. The cDNA encoding the novel heregulin 2-.alpha. has been isolated from human tissue and sequenced. Provided herein is nucleic acid sequence of the heregulin 2-.alpha. useful in the production of heregulin 2-.alpha. by recombinant means. Further provided an amino acid sequence of heregulin 2-.alpha. and heregulin 2-.beta.. Heregulins and their antibodies are useful as therapeutic agents and in diagnostic methods.
    Type: Grant
    Filed: October 25, 1994
    Date of Patent: November 10, 1998
    Assignee: Genentech, Inc.
    Inventors: Richard L. Vandlen, William E. Holmes
  • Patent number: 5783415
    Abstract: The cDNA encoding a member of or a class of novel PF4A receptors has been identified in human tissue. Provided herein is nucleic acid sequence of a PF4A receptor (the IL-8 receptor) useful as a diagnostic and in the recombinant preparation of PF4A receptors. The PF4A receptor is used in the preparation and purification of antibodies capable of binding to the receptor, and in diagnostic assays.
    Type: Grant
    Filed: March 24, 1995
    Date of Patent: July 21, 1998
    Assignee: Genentech, Inc.
    Inventors: James Lee, William E. Holmes, William I. Wood
  • Patent number: 5767063
    Abstract: The cDNA encoding a member of or a class of novel PF4A receptors has been identified in human tissue. Provided herein is nucleic acid sequence of a PF4A receptor (the IL-8 receptor) useful as a diagnostic and in the recombinant preparation of PF4A receptors. The PF4A receptor is used in the preparation and purification of antibodies capable of binding to the receptor, and in diagnostic assays.
    Type: Grant
    Filed: March 24, 1995
    Date of Patent: June 16, 1998
    Assignee: Genentech, Inc.
    Inventors: James Lee, William E. Holmes, William I. Wood
  • Patent number: 5641869
    Abstract: A novel polypeptide with binding affinity for the p185.sup.HER2 receptor, designated heregulin-.alpha., has been identified and purified from cultured human cells. DNA sequences encoding additional heregulin polypeptides, designated heregulin-.alpha., heregulin-.beta.1, heregulin-.beta.2, heregulin-.beta.2-like, and heregulin-.beta.3, have been isolated, sequenced and expressed. Provided herein are nucleic acid sequences encoding the amino acid sequences of heregulins useful in the production of heregulins by recombinant means. Further provided are the amino acid sequences of heregulins and purification methods therefor. Heregulins and their antibodies are useful as therapeutic agents and in diagnostic methods.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: June 24, 1997
    Assignee: Genentech, Inc.
    Inventors: Richard L. Vandlen, William E. Holmes
  • Patent number: 5633141
    Abstract: The cDNA encoding a member of or a class of novel PF4A receptors has been identified in human tissue. Provided herein is nucleic acid sequence of a PF4A receptor (the IL-8 receptor) useful as a diagnostic and in the recombinant preparation of PF4A receptors. The PF4A receptor is used in the preparation and purification of antibodies capable of binding to the receptor, and in diagnostic assays.
    Type: Grant
    Filed: April 7, 1995
    Date of Patent: May 27, 1997
    Assignee: Genentech, Inc.
    Inventors: James Lee, William E. Holmes, William I. Wood
  • Patent number: 5571702
    Abstract: The cDNA encoding a member of or a class of novel PF4A receptors has been identified in human tissue. Provided herein is nucleic acid sequence of a PF4A receptor (the IL-8 receptor) useful as a diagnostic and in the recombinant preparation of PF4A receptors. The PF4A receptor is used in the preparation and purification of antibodies capable of binding to the receptor, and in diagnostic assays.
    Type: Grant
    Filed: March 24, 1995
    Date of Patent: November 5, 1996
    Assignee: Genentech, Inc.
    Inventors: James Lee, William E. Holmes, William I. Wood
  • Patent number: 5552284
    Abstract: The cDNA encoding a member of or a class of novel PF4A receptors has been identified in human tissue. Provided herein is nucleic acid sequence of a PF4A receptor (the IL-8 receptor) useful as a diagnostic and in the recombinant preparation of PF4A receptors. The PF4A receptor is used in the preparation and purification of antibodies capable of binding to the receptor, and in diagnostic assays.
    Type: Grant
    Filed: March 24, 1995
    Date of Patent: September 3, 1996
    Assignee: Genentech, Inc.
    Inventors: James Lee, William E. Holmes, William I. Wood
  • Patent number: 5367060
    Abstract: A novel polypeptide with binding affinity for the p185.sup.HER2 receptor, designated heregulin-.alpha., has been identified and purified from cultured human cells. DNA sequences encoding additional heregulin polypeptides, designated heregulin-.alpha., heregulin-.beta.1, heregulin-.beta.2, heregulin-.beta.2-like, and heregulin-.beta.3, have been isolated, sequenced and expressed. Provided herein are nucleic acid sequences encoding the amino acid sequences of heregulins useful in the production of heregulins by recombinant means. Further provided are the amino acid sequences of heregulins and purification methods therefor. Heregulins and their antibodies are useful as therapeutic agents and in diagnostic methods.
    Type: Grant
    Filed: March 6, 1992
    Date of Patent: November 22, 1994
    Assignee: Genentech, Inc.
    Inventors: Richard L. Vandlen, William E. Holmes
  • Patent number: 5112755
    Abstract: Human urokinase is produced using recombinant DNA techniques. The invention disclosed thus enables the production of urokinase free of contaminants with which it is ordinarily associated in its native cellular environment. Methods, expression vehicles and various host cells useful in its production are also disclosed.
    Type: Grant
    Filed: July 19, 1988
    Date of Patent: May 12, 1992
    Assignee: Genentech, Inc.
    Inventors: Herbert L. Heyneker, William E. Holmes, Gordon A. Vehar